Galmed Pharmaceuticals Ltd.
No SEC Form 4 filings for $GLMD in the last 30 days.
See all $GLMD insider activity →Galmed Pharmaceuticals (GLMD) reported first preclinical results that its Aramchol SCD1 inhibitor plus enzalutamide (Xtandi) increased prostate cancer cell death 3-4x versus enzalutamide alone in VCaP cells. The effect grew with longer exposure, suggesting possible delay of resistance. GLMD stock was about $0.58, up 9.23%.
Galmed Pharmaceuticals (NASDAQ: GLMD) said Nasdaq granted an additional 180 days, extending the deadline to Jan. 25, 2027, to regain compliance with the $1 minimum bid price rule. Nasdaq initially notified GLMD on Jan. 29, 2026, and the prior deadline was July 28, 2026. Compliance requires a $1 or higher close for 10 straight trading days.
Galmed Pharmaceuticals (NASDAQ:GLMD) said its orally dispersible film formulation of Aramchol for Parkinson’s aims to improve drug delivery. The company reported about 150% higher systemic bioavailability and about 300% higher CNS exposure versus conventional oral dosing, with rapid dissolution and buccal/sublingual absorption, per its press release.
Over the past 7 days, alphai's AI scored 1 news story mentioning GLMD (Galmed Pharmaceuticals Ltd.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent GLMD coverage spans financial news, technology and corporate actions.
Preclinical combination efficacy supports a potential future clinical rationale for Aramchol with enzalutamide, but it is not yet a clinical or regulatory catalyst.
The extension reduces near-term delisting risk, but keeps the company in an active Nasdaq compliance process.
Higher CNS exposure and faster, waterless dissolution are positioned as a formulation advance that could support future co-development or out-licensing discussions.
Galmed announced a novel brain-penetrant formulation of Aramchol, expanding its potential into CNS indications. This development could positively impact Galmed's valuation if clinical progress is successful, but the current market sentiment remains somewhat bearish.
The postponement of Galmed Pharmaceuticals' shareholder meeting is unlikely to have a significant immediate impact on the stock price or trading activity.
alphai scores every news story that mentions GLMD with an AI model for sentiment and relevance, and aggregates insider trades from Galmed Pharmaceuticals Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Galmed Pharmaceuticals (GLMD) reported first preclinical results that its Aramchol SCD1 inhibitor plus enzalutamide (Xtandi) increased prostate cancer cell death 3-4x versus enzalutamide alone in VCaP cells. The effect grew with longer exposure, suggesting possible delay of resistance. GLMD stock was about $0.58, up 9.23%.
3 min readGalmed Pharmaceuticals (NASDAQ: GLMD) said Nasdaq granted an additional 180 days, extending the deadline to Jan. 25, 2027, to regain compliance with the $1 minimum bid price rule. Nasdaq initially notified GLMD on Jan. 29, 2026, and the prior deadline was July 28, 2026. Compliance requires a $1 or higher close for 10 straight trading days.
2 min readGalmed Pharmaceuticals (NASDAQ:GLMD) said its orally dispersible film formulation of Aramchol for Parkinson’s aims to improve drug delivery. The company reported about 150% higher systemic bioavailability and about 300% higher CNS exposure versus conventional oral dosing, with rapid dissolution and buccal/sublingual absorption, per its press release.
4 min readGalmed Pharmaceuticals announced a new brain-penetrant formulation of its drug Aramchol, co-developed with Barcode Nanotech. This new formulation, delivered via lipid nanoparticles, can cross the blood-brain barrier and is intended to treat synucleinopathies like Parkinson's disease. The development expands Aramchol's potential from liver diseases into high-unmet-need Central Nervous System indications, leveraging AI-enabled screening for optimal delivery.
4 min readGalmed Pharmaceuticals Ltd. (GLMD) has adjourned its Special General Meeting of Shareholders due to a lack of quorum. The meeting, originally scheduled for March 4, 2026, will now reconvene on March 5, 2026, at 4:00 p.m. Israel time at the offices of Meitar Law Offices. This information has been incorporated by reference into the company's existing Form S-8 and Form F-3 registration statements.
1 min readU.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 200 points on Monday. The Dow traded down 0.27% to 40,004.11 while the NASDAQ fell 1.19% to 17,175.43. The S&P 500 also fell, dropping, 0.72% to 5,485.36. Financial shares jumped by 0.6% on Monday.
4 min read
